Analysts’ Top Healthcare Picks: OBLN, LH

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Obalon Therapeutics Inc (NASDAQ: OBLN), Laboratory Corp (NYSE: LH) and Immune Design (NASDAQ: IMDZ) with bullish sentiments.

Obalon Therapeutics Inc (NASDAQ: OBLN)

Canaccord Genuity analyst Kyle Rose reiterated a Buy rating on Obalon Therapeutics Inc (NASDAQ: OBLN) yesterday and set a price target of $20. The company’s shares opened today at $10.11.

Rose wrote:

“We reiterate our BUY rating following marketing meetings with management. We recently hosted two days of upbeat investor meetings with Obalon CEO Andy Rasdal as well as CFO Bill Plovanic. We came away from those meetings with a clearer understanding of investor sentiment as well as early commercial traction in the US launch.”

According to TipRanks.com, Rose is a 3-star analyst with an average return of 3.0% and a 46.5% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Zeltiq Aesthetics, and Enteromedics Inc.

Currently, the analyst consensus on Obalon Therapeutics Inc is Moderate Buy and the average price target is $20, representing a 97.8% upside.

In a report issued on May 11, BTIG also reiterated a Buy rating on the stock with a $20 price target.
Laboratory Corp (NYSE: LH)

In a report released yesterday, Mark Massaro from Canaccord Genuity reiterated a Buy rating on Laboratory Corp (NYSE: LH), with a price target of $155. The company’s shares opened today at $137.64.

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 12.2% and a 60.3% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quest Diagnostics Inc.

Laboratory Corp has an analyst consensus of Strong Buy, with a price target consensus of $160.50.

Immune Design (NASDAQ: IMDZ)

Cowen & Co. analyst Boris Peaker reiterated a Buy rating on Immune Design (NASDAQ: IMDZ) yesterday. The company’s shares opened today at $6.40.

Peaker observed:

“IMDZ reported 1Q earnings and provided a pipeline update.”

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.8% and a 42.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, and Merrimack Pharmaceuticals.

Immune Design has an analyst consensus of Moderate Buy, with a price target consensus of $15.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.